journal article·2026-05-27

CaO 2 -Powered Nanomotors with Enhanced Cellular Uptake and Lysosomal Escape for Cuproptosis and Reactive Oxygen Species-Mediated Synergistic Cancer Therapy

Xuemei Ma, Yue Feng, Tianliang Lin, Qiting Xie, Yulan Hu, Yijin Wu, Zhongxiang Zhao, Yuxing Ji

ACS Applied Materials & Interfaces· Volume 18· Issue 20
Publisher page

Abstract

Low cellular uptake and lysosomal degradation of nanomaterials in tumors pose a major challenge for reactive oxygen species (ROS)-involved chemodynamic therapy. Here, we report a self-propelled polyethylenimine-modified calcium peroxide@bovine serum albumin/copper/catalase-hesperidin (CaO 2 –PEI@BSA/Cu/CAT@HES, CP@BCC-HES) nanomotor capable of enhancing diffusion and cellular uptake. This nanomotor is engineered by incorporating Cu-based nanoparticles into functionalized CaO 2 nanoparticles, followed by Hesperidin loading for systematic tumor therapy. Upon cellular internalization, nanomotors efficiently escape lysosomal entrapment, owing to the proton sponge effect. In acidic tumor microenvironments, sustained release of Ca 2+, Cu 2+, hydrogen peroxide (H 2 O 2 ), and hesperidin occurs, triggering a cascade of therapeutic effects. Notably, Cu 2+ and H 2 O 2 engage in an amplified Fenton-type reaction, yielding abundant hydroxyl radicals. Further, intracellular Cu 2+ accumulation induces ROS overproduction and dihydrolipoamide s-acetyltransferase heterodimerization, resulting in cuproptosis. Intriguingly, hesperidin and excessive ROS synergistically facilitate intracellular Ca 2+ accumulation, leading to calcification, mitochondrial dysfunction, and ROS imbalance, ultimately inducing tumor cell death. Moreover, these self-propelled nanomotors demonstrate superior tumor penetration and accumulation, as evidenced by robust antitumor efficacy in both in vitro and in vivo studies. Collectively, the self-propelled nanomotor system represents a promising method for improving intratumoral delivery and ROS generation, thereby enhancing the therapeutic outcomes of chemodynamic therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Micro and Nano Robotics · Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmaceutical Sciences

Guangzhou University of Chinese Medicine

Funding

National Natural Science Foundation of China (NSFC)

References (44)

Show source-provided references
1. 10.1038/s41573-024-00979-410.1038/s41573-024-00979-4 ↗
2. 10.1016/j.biomaterials.2024.12283510.1016/j.biomaterials.2024.122835 ↗
3. 10.1016/j.biomaterials.2024.12300410.1016/j.biomaterials.2024.123004 ↗
4. 10.1021/acsnano.4c1375310.1021/acsnano.4c13753 ↗
5. 10.1016/j.apsb.2024.05.02910.1016/j.apsb.2024.05.029 ↗
6. 10.1002/adfm.20231456810.1002/adfm.202314568 ↗
7. 10.1016/j.biomaterials.2025.12332210.1016/j.biomaterials.2025.123322 ↗
8. 10.1021/acsnano.3c0777510.1021/acsnano.3c07775 ↗
9. 10.1016/j.jconrel.2026.11477210.1016/j.jconrel.2026.114772 ↗
10. 10.1002/adhm.20220215010.1002/adhm.202202150 ↗
11. 10.1002/adma.20210422310.1002/adma.202104223 ↗
12. 10.1002/advs.20210024110.1002/advs.202100241 ↗
13. 10.1016/j.biomaterials.2024.12302710.1016/j.biomaterials.2024.123027 ↗
14. 10.1021/acsami.4c1274810.1021/acsami.4c12748 ↗
15. 10.1016/j.biomaterials.2023.12228410.1016/j.biomaterials.2023.122284 ↗
16. 10.1016/j.jcis.2023.10.09210.1016/j.jcis.2023.10.092 ↗
17. 10.1021/acsami.5c2454910.1021/acsami.5c24549 ↗
18. 10.1016/j.apsb.2021.08.01210.1016/j.apsb.2021.08.012 ↗
19. 10.1021/acs.molpharmaceut.4c0049010.1021/acs.molpharmaceut.4c00490 ↗
20. 10.1016/j.biomaterials.2021.12095510.1016/j.biomaterials.2021.120955 ↗
21. 10.1021/acsbiomaterials.4c0161210.1021/acsbiomaterials.4c01612 ↗
22. 10.1186/s12885-015-1706-y10.1186/s12885-015-1706-y ↗
23. 10.1021/acsnano.3c1021210.1021/acsnano.3c10212 ↗
24. 10.1021/acsnano.5c0512810.1021/acsnano.5c05128 ↗
25. 10.1002/adma.20250886510.1002/adma.202508865 ↗
26. 10.1002/adhm.20240016310.1002/adhm.202400163 ↗
27. 10.1002/adma.20220574610.1002/adma.202205746 ↗
28. 10.1021/acsnano.4c1272610.1021/acsnano.4c12726 ↗
29. 10.1016/j.jcis.2023.05.17210.1016/j.jcis.2023.05.172 ↗
30. 10.1016/j.mtbio.2025.10154010.1016/j.mtbio.2025.101540 ↗
31. 10.1021/acsami.4c1785210.1021/acsami.4c17852 ↗
32. 10.1021/acsanm.4c0593110.1021/acsanm.4c05931 ↗
33. 10.1016/j.cclet.2020.06.03110.1016/j.cclet.2020.06.031 ↗
34. 10.1016/j.cej.2016.08.08110.1016/j.cej.2016.08.081 ↗
35. 10.1016/j.carbpol.2018.01.04010.1016/j.carbpol.2018.01.040 ↗
36. 10.1021/acsami.8b1680110.1021/acsami.8b16801 ↗
37. 10.1002/advs.20230191910.1002/advs.202301919 ↗
38. 10.1002/smll.20220404710.1002/smll.202204047 ↗
39. 10.1021/acsnano.2c0032710.1021/acsnano.2c00327 ↗
40. 10.1002/anbr.20210012410.1002/anbr.202100124 ↗
41. 10.1016/j.mtbio.2024.10129910.1016/j.mtbio.2024.101299 ↗
42. 10.1016/j.cej.2024.15337210.1016/j.cej.2024.153372 ↗
43. 10.1002/advs.20250412110.1002/advs.202504121 ↗
44. 10.1016/j.biomaterials.2024.12302710.1016/j.biomaterials.2024.123027 ↗